| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 165 | 2024 | 973 | 32.900 |
Why?
|
| Lung Neoplasms | 211 | 2024 | 2199 | 32.180 |
Why?
|
| Protein Kinase Inhibitors | 92 | 2023 | 795 | 13.610 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 47 | 2022 | 227 | 10.500 |
Why?
|
| Antineoplastic Agents | 78 | 2024 | 1895 | 10.310 |
Why?
|
| Pyrimidines | 33 | 2022 | 378 | 7.520 |
Why?
|
| Pyrazoles | 46 | 2023 | 364 | 7.520 |
Why?
|
| Pyridines | 38 | 2021 | 425 | 6.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 41 | 2023 | 1361 | 6.270 |
Why?
|
| Organophosphorus Compounds | 17 | 2022 | 72 | 5.670 |
Why?
|
| Gene Rearrangement | 26 | 2022 | 138 | 5.570 |
Why?
|
| ErbB Receptors | 52 | 2023 | 560 | 5.540 |
Why?
|
| Protein-Tyrosine Kinases | 29 | 2024 | 398 | 4.760 |
Why?
|
| Brain Neoplasms | 30 | 2023 | 984 | 4.640 |
Why?
|
| Drug Resistance, Neoplasm | 31 | 2021 | 642 | 3.720 |
Why?
|
| Proto-Oncogene Proteins c-met | 21 | 2022 | 69 | 3.700 |
Why?
|
| Proto-Oncogene Proteins | 29 | 2024 | 610 | 3.490 |
Why?
|
| Immunoconjugates | 7 | 2022 | 87 | 2.990 |
Why?
|
| Carbazoles | 13 | 2022 | 78 | 2.860 |
Why?
|
| Neoplasms | 29 | 2022 | 2105 | 2.740 |
Why?
|
| Humans | 275 | 2024 | 114756 | 2.660 |
Why?
|
| Mutation | 54 | 2023 | 3350 | 2.650 |
Why?
|
| Piperidines | 12 | 2022 | 161 | 2.630 |
Why?
|
| Small Cell Lung Carcinoma | 14 | 2023 | 82 | 2.440 |
Why?
|
| Oncogenes | 8 | 2024 | 107 | 2.430 |
Why?
|
| Adenocarcinoma | 16 | 2017 | 801 | 2.400 |
Why?
|
| Middle Aged | 127 | 2021 | 26757 | 2.320 |
Why?
|
| Acrylamides | 12 | 2022 | 41 | 2.120 |
Why?
|
| Aged | 105 | 2022 | 19094 | 2.050 |
Why?
|
| Clinical Trials as Topic | 17 | 2022 | 935 | 2.020 |
Why?
|
| Biomarkers, Tumor | 24 | 2021 | 1053 | 2.010 |
Why?
|
| Molecular Targeted Therapy | 14 | 2022 | 347 | 1.990 |
Why?
|
| Thoracic Neoplasms | 3 | 2019 | 32 | 1.800 |
Why?
|
| Antibodies, Monoclonal, Humanized | 19 | 2022 | 664 | 1.790 |
Why?
|
| Antibodies, Monoclonal | 17 | 2023 | 1270 | 1.770 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2021 | 179 | 1.710 |
Why?
|
| Male | 135 | 2021 | 55579 | 1.710 |
Why?
|
| Radiosurgery | 12 | 2023 | 302 | 1.680 |
Why?
|
| Female | 137 | 2024 | 59507 | 1.650 |
Why?
|
| Aged, 80 and over | 58 | 2021 | 6350 | 1.650 |
Why?
|
| In Situ Hybridization, Fluorescence | 15 | 2021 | 313 | 1.610 |
Why?
|
| Lung Diseases, Interstitial | 5 | 2022 | 507 | 1.590 |
Why?
|
| Erlotinib Hydrochloride | 13 | 2022 | 65 | 1.580 |
Why?
|
| Quinazolines | 11 | 2017 | 243 | 1.550 |
Why?
|
| Adult | 98 | 2023 | 30548 | 1.510 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 5 | 2013 | 26 | 1.480 |
Why?
|
| Neoplasm Staging | 29 | 2022 | 1176 | 1.460 |
Why?
|
| Lactams, Macrocyclic | 8 | 2023 | 46 | 1.430 |
Why?
|
| Mesothelioma | 4 | 2018 | 31 | 1.410 |
Why?
|
| Central Nervous System | 4 | 2021 | 237 | 1.360 |
Why?
|
| Disease-Free Survival | 26 | 2020 | 623 | 1.270 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 13 | 2023 | 229 | 1.250 |
Why?
|
| Gene Dosage | 4 | 2018 | 134 | 1.250 |
Why?
|
| Survival Rate | 23 | 2021 | 1642 | 1.250 |
Why?
|
| Circulating Tumor DNA | 4 | 2022 | 23 | 1.240 |
Why?
|
| Cell-Free Nucleic Acids | 4 | 2022 | 28 | 1.180 |
Why?
|
| Maximum Tolerated Dose | 20 | 2021 | 184 | 1.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2021 | 46 | 1.120 |
Why?
|
| Aniline Compounds | 9 | 2023 | 70 | 1.120 |
Why?
|
| Trastuzumab | 3 | 2022 | 89 | 1.110 |
Why?
|
| Imidazoles | 4 | 2018 | 211 | 1.110 |
Why?
|
| Retrospective Studies | 38 | 2023 | 12515 | 1.100 |
Why?
|
| Prognosis | 27 | 2022 | 3334 | 1.090 |
Why?
|
| Camptothecin | 5 | 2022 | 98 | 1.080 |
Why?
|
| Piperazines | 3 | 2019 | 311 | 1.080 |
Why?
|
| Exons | 10 | 2022 | 303 | 1.020 |
Why?
|
| Treatment Outcome | 42 | 2024 | 9089 | 1.020 |
Why?
|
| Cell Cycle | 6 | 2012 | 543 | 1.010 |
Why?
|
| Receptor, ErbB-2 | 9 | 2020 | 301 | 0.990 |
Why?
|
| Follow-Up Studies | 25 | 2021 | 4420 | 0.970 |
Why?
|
| Disease Progression | 17 | 2022 | 2387 | 0.970 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 6 | 2022 | 14 | 0.960 |
Why?
|
| B7-H1 Antigen | 5 | 2022 | 142 | 0.960 |
Why?
|
| Apoptosis | 8 | 2023 | 2369 | 0.950 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2021 | 25 | 0.920 |
Why?
|
| Immunotherapy | 5 | 2021 | 475 | 0.900 |
Why?
|
| Pleural Neoplasms | 3 | 2018 | 18 | 0.890 |
Why?
|
| Neoplasm Metastasis | 12 | 2020 | 528 | 0.880 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 604 | 0.870 |
Why?
|
| Neuregulin-1 | 2 | 2021 | 40 | 0.830 |
Why?
|
| Medical Oncology | 4 | 2022 | 229 | 0.820 |
Why?
|
| Paclitaxel | 9 | 2020 | 190 | 0.810 |
Why?
|
| Pyridazines | 3 | 2019 | 49 | 0.810 |
Why?
|
| Hypogonadism | 2 | 2013 | 75 | 0.800 |
Why?
|
| Endpoint Determination | 5 | 2018 | 69 | 0.800 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 863 | 0.800 |
Why?
|
| Survival Analysis | 11 | 2021 | 1218 | 0.790 |
Why?
|
| Glutamates | 6 | 2014 | 58 | 0.780 |
Why?
|
| Guanine | 6 | 2014 | 76 | 0.770 |
Why?
|
| Carboplatin | 11 | 2021 | 135 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2021 | 1846 | 0.750 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2023 | 126 | 0.750 |
Why?
|
| Lactams | 8 | 2023 | 18 | 0.750 |
Why?
|
| ras Proteins | 8 | 2014 | 138 | 0.740 |
Why?
|
| Authorship | 1 | 2021 | 31 | 0.740 |
Why?
|
| Biomarkers | 8 | 2019 | 3416 | 0.740 |
Why?
|
| Patient Selection | 5 | 2019 | 641 | 0.740 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 51 | 0.720 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2013 | 173 | 0.710 |
Why?
|
| Aminopyridines | 8 | 2023 | 81 | 0.710 |
Why?
|
| Kidney | 2 | 2019 | 1184 | 0.700 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 152 | 0.700 |
Why?
|
| Pneumonia | 2 | 2022 | 566 | 0.680 |
Why?
|
| DNA Copy Number Variations | 6 | 2022 | 158 | 0.660 |
Why?
|
| Testosterone | 2 | 2013 | 343 | 0.650 |
Why?
|
| Taxoids | 6 | 2023 | 94 | 0.650 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2018 | 193 | 0.630 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 242 | 0.630 |
Why?
|
| Gene Amplification | 9 | 2019 | 97 | 0.630 |
Why?
|
| Young Adult | 22 | 2020 | 10463 | 0.620 |
Why?
|
| Kidney Neoplasms | 2 | 2013 | 333 | 0.620 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2010 | 111 | 0.600 |
Why?
|
| Thromboembolism | 1 | 2018 | 93 | 0.600 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 479 | 0.600 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2020 | 815 | 0.590 |
Why?
|
| Drug Administration Schedule | 10 | 2017 | 718 | 0.590 |
Why?
|
| Pyrazines | 2 | 2019 | 71 | 0.580 |
Why?
|
| Creatinine | 2 | 2019 | 424 | 0.570 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 507 | 0.560 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2016 | 63 | 0.520 |
Why?
|
| Mouth Mucosa | 2 | 2006 | 79 | 0.520 |
Why?
|
| Hair | 2 | 2006 | 65 | 0.510 |
Why?
|
| Indoles | 6 | 2021 | 306 | 0.500 |
Why?
|
| Cranial Irradiation | 7 | 2022 | 67 | 0.490 |
Why?
|
| Triazoles | 2 | 2013 | 130 | 0.490 |
Why?
|
| Cohort Studies | 13 | 2021 | 4901 | 0.470 |
Why?
|
| Nitrofurantoin | 1 | 2014 | 7 | 0.470 |
Why?
|
| Pemetrexed | 6 | 2014 | 27 | 0.470 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2014 | 13 | 0.460 |
Why?
|
| Cystitis | 1 | 2014 | 20 | 0.460 |
Why?
|
| Signal Transduction | 8 | 2014 | 4521 | 0.460 |
Why?
|
| RNA, Messenger | 3 | 2018 | 2557 | 0.460 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 16 | 0.450 |
Why?
|
| Crown Ethers | 1 | 2013 | 4 | 0.450 |
Why?
|
| Blood-Brain Barrier | 2 | 2016 | 106 | 0.440 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 584 | 0.420 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2009 | 23 | 0.410 |
Why?
|
| Smoking | 2 | 2018 | 1384 | 0.400 |
Why?
|
| Point Mutation | 1 | 2013 | 216 | 0.400 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 13 | 0.400 |
Why?
|
| Sulfonamides | 5 | 2020 | 445 | 0.400 |
Why?
|
| Tissue Distribution | 5 | 2020 | 285 | 0.400 |
Why?
|
| Organoplatinum Compounds | 3 | 2012 | 37 | 0.400 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 58 | 0.390 |
Why?
|
| Adolescent | 13 | 2022 | 17808 | 0.390 |
Why?
|
| Cell Proliferation | 8 | 2014 | 2196 | 0.380 |
Why?
|
| Androgens | 1 | 2013 | 167 | 0.380 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 94 | 0.380 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 14 | 0.380 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 171 | 0.370 |
Why?
|
| Keratin-18 | 1 | 2010 | 10 | 0.360 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 954 | 0.360 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2016 | 20 | 0.350 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2009 | 286 | 0.350 |
Why?
|
| Benzamides | 2 | 2022 | 169 | 0.350 |
Why?
|
| Estrenes | 1 | 2010 | 15 | 0.350 |
Why?
|
| Lung | 4 | 2019 | 3546 | 0.340 |
Why?
|
| Antimitotic Agents | 1 | 2009 | 8 | 0.340 |
Why?
|
| Estradiol | 2 | 2010 | 455 | 0.340 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 190 | 0.340 |
Why?
|
| Receptors, Somatomedin | 1 | 2009 | 3 | 0.340 |
Why?
|
| Catheter Ablation | 1 | 2012 | 291 | 0.330 |
Why?
|
| Caspase 3 | 1 | 2010 | 236 | 0.330 |
Why?
|
| Genetic Testing | 2 | 2015 | 379 | 0.330 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2001 | 181 | 0.330 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2019 | 195 | 0.320 |
Why?
|
| Mitosis | 1 | 2009 | 164 | 0.310 |
Why?
|
| Sulfones | 4 | 2021 | 97 | 0.310 |
Why?
|
| Genotype | 4 | 2021 | 1774 | 0.310 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 280 | 0.310 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 141 | 0.310 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2008 | 100 | 0.300 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 2725 | 0.300 |
Why?
|
| Immunohistochemistry | 5 | 2022 | 1635 | 0.290 |
Why?
|
| Administration, Oral | 8 | 2015 | 731 | 0.290 |
Why?
|
| HIV | 1 | 2008 | 208 | 0.290 |
Why?
|
| Quality of Life | 5 | 2021 | 2358 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2006 | 7 | 0.280 |
Why?
|
| Accidents | 1 | 2007 | 38 | 0.280 |
Why?
|
| Etoposide | 4 | 2021 | 148 | 0.270 |
Why?
|
| Quinazolinones | 3 | 2016 | 19 | 0.270 |
Why?
|
| Cell Adhesion Molecules | 2 | 2017 | 168 | 0.270 |
Why?
|
| Ethics, Medical | 1 | 2006 | 70 | 0.270 |
Why?
|
| Time Factors | 7 | 2021 | 6124 | 0.270 |
Why?
|
| Pharmacology | 1 | 2005 | 8 | 0.260 |
Why?
|
| Pharmacokinetics | 1 | 2005 | 25 | 0.260 |
Why?
|
| Technology, Pharmaceutical | 1 | 2005 | 19 | 0.260 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 222 | 0.260 |
Why?
|
| Registries | 4 | 2021 | 1759 | 0.250 |
Why?
|
| Precision Medicine | 4 | 2019 | 338 | 0.250 |
Why?
|
| DNA, Neoplasm | 2 | 2019 | 157 | 0.240 |
Why?
|
| Cough | 2 | 2017 | 107 | 0.240 |
Why?
|
| Mortality | 1 | 2007 | 288 | 0.240 |
Why?
|
| RNA | 3 | 2019 | 810 | 0.230 |
Why?
|
| Animals | 16 | 2024 | 31761 | 0.230 |
Why?
|
| Immunoenzyme Techniques | 3 | 2014 | 195 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 493 | 0.230 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 84 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 545 | 0.230 |
Why?
|
| Prospective Studies | 6 | 2023 | 6217 | 0.220 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1122 | 0.220 |
Why?
|
| Radiotherapy Dosage | 3 | 2017 | 245 | 0.220 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 8 | 0.220 |
Why?
|
| Fertility | 1 | 2024 | 130 | 0.210 |
Why?
|
| Platinum | 1 | 2023 | 38 | 0.210 |
Why?
|
| Tumor Burden | 3 | 2018 | 261 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2022 | 2269 | 0.210 |
Why?
|
| Pyrroles | 3 | 2012 | 183 | 0.210 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 71 | 0.200 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 372 | 0.200 |
Why?
|
| Treatment Failure | 3 | 2014 | 332 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 53 | 0.200 |
Why?
|
| Indazoles | 1 | 2022 | 58 | 0.190 |
Why?
|
| Fatigue | 5 | 2015 | 295 | 0.190 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 1868 | 0.190 |
Why?
|
| Benzodiazepinones | 1 | 2021 | 14 | 0.190 |
Why?
|
| Pregnancy | 2 | 2024 | 5525 | 0.190 |
Why?
|
| Nails, Malformed | 1 | 2001 | 5 | 0.190 |
Why?
|
| Lymphoma, Follicular | 1 | 2021 | 35 | 0.190 |
Why?
|
| Skin | 1 | 2005 | 659 | 0.190 |
Why?
|
| Research Design | 5 | 2016 | 931 | 0.180 |
Why?
|
| Recurrence | 3 | 2018 | 936 | 0.180 |
Why?
|
| Carcinogenesis | 1 | 2022 | 180 | 0.180 |
Why?
|
| Suicide | 1 | 2007 | 502 | 0.180 |
Why?
|
| Biopsy | 3 | 2013 | 1040 | 0.180 |
Why?
|
| Epidermal Cyst | 1 | 2000 | 12 | 0.180 |
Why?
|
| Bevacizumab | 2 | 2019 | 115 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 3 | 2012 | 283 | 0.180 |
Why?
|
| Retreatment | 2 | 2017 | 67 | 0.170 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 87 | 0.170 |
Why?
|
| Standard of Care | 1 | 2020 | 62 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 213 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 101 | 0.170 |
Why?
|
| Radiodermatitis | 1 | 2000 | 7 | 0.170 |
Why?
|
| Positron-Emission Tomography | 4 | 2014 | 259 | 0.170 |
Why?
|
| Policy | 1 | 2021 | 137 | 0.170 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2019 | 16 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 196 | 0.170 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 275 | 0.170 |
Why?
|
| Cisplatin | 4 | 2014 | 263 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 86 | 0.170 |
Why?
|
| Incidence | 3 | 2020 | 2312 | 0.170 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 9 | 0.170 |
Why?
|
| Diarrhea | 2 | 2017 | 173 | 0.170 |
Why?
|
| Organs at Risk | 1 | 2019 | 30 | 0.170 |
Why?
|
| Motivation | 1 | 2023 | 494 | 0.160 |
Why?
|
| Aminoquinolines | 1 | 2019 | 20 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 98 | 0.160 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2019 | 13 | 0.160 |
Why?
|
| Oncogene Proteins | 1 | 2019 | 53 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2012 | 498 | 0.160 |
Why?
|
| Radiotherapy, Conformal | 2 | 2017 | 68 | 0.160 |
Why?
|
| Gene Fusion | 1 | 2018 | 18 | 0.160 |
Why?
|
| Antinematodal Agents | 1 | 2018 | 5 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 59 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 82 | 0.150 |
Why?
|
| Gold | 1 | 2019 | 106 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 1435 | 0.150 |
Why?
|
| Drug Approval | 1 | 2018 | 78 | 0.150 |
Why?
|
| Hospitalization | 1 | 2007 | 1752 | 0.150 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 195 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 276 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 1080 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 333 | 0.150 |
Why?
|
| United States | 6 | 2022 | 12176 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1340 | 0.150 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 248 | 0.140 |
Why?
|
| Drowning | 1 | 2017 | 7 | 0.140 |
Why?
|
| Benzimidazoles | 3 | 2018 | 138 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 436 | 0.140 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
|
| Thymoma | 1 | 2017 | 30 | 0.140 |
Why?
|
| Scotland | 2 | 2007 | 12 | 0.140 |
Why?
|
| Receptors, Growth Factor | 3 | 2011 | 49 | 0.140 |
Why?
|
| Nausea | 1 | 2017 | 103 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 206 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 316 | 0.130 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2016 | 14 | 0.130 |
Why?
|
| Headache | 1 | 2017 | 132 | 0.130 |
Why?
|
| Centrosome | 1 | 2016 | 60 | 0.130 |
Why?
|
| Decision Trees | 1 | 2016 | 80 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 63 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2015 | 2973 | 0.130 |
Why?
|
| Markov Chains | 1 | 2016 | 114 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1214 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2014 | 1590 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 54 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2017 | 219 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2018 | 3039 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2022 | 182 | 0.120 |
Why?
|
| Drug Interactions | 2 | 2013 | 340 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 928 | 0.120 |
Why?
|
| Neutropenia | 4 | 2019 | 125 | 0.120 |
Why?
|
| Structure-Activity Relationship | 2 | 2018 | 503 | 0.120 |
Why?
|
| HIV Infections | 1 | 2008 | 2469 | 0.120 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2014 | 17 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2006 | 2763 | 0.120 |
Why?
|
| Australia | 2 | 2012 | 207 | 0.120 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2014 | 40 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 728 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 181 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2013 | 86 | 0.110 |
Why?
|
| Disease Management | 2 | 2020 | 560 | 0.110 |
Why?
|
| Threonine | 1 | 2013 | 40 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 761 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2016 | 176 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2013 | 48 | 0.110 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 43 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 66 | 0.100 |
Why?
|
| Biomedical Research | 2 | 2010 | 585 | 0.100 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIb | 1 | 2012 | 9 | 0.100 |
Why?
|
| Methionine | 1 | 2013 | 144 | 0.100 |
Why?
|
| Dyspnea | 1 | 2014 | 213 | 0.100 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Luteinizing Hormone | 1 | 2013 | 169 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2013 | 134 | 0.100 |
Why?
|
| Heterozygote | 1 | 2013 | 251 | 0.100 |
Why?
|
| Thiophenes | 1 | 2013 | 108 | 0.100 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2012 | 27 | 0.100 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2013 | 216 | 0.100 |
Why?
|
| Biological Transport | 1 | 2013 | 372 | 0.100 |
Why?
|
| Quinolines | 1 | 2013 | 129 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 647 | 0.100 |
Why?
|
| Glioma | 1 | 2015 | 294 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 82 | 0.100 |
Why?
|
| Genes, ras | 1 | 2012 | 91 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 80 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2015 | 292 | 0.100 |
Why?
|
| Niacinamide | 1 | 2012 | 64 | 0.100 |
Why?
|
| Mutagenesis, Insertional | 2 | 2022 | 61 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2014 | 1151 | 0.100 |
Why?
|
| Models, Molecular | 2 | 2018 | 1378 | 0.100 |
Why?
|
| Radiation Pneumonitis | 1 | 2011 | 26 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 26 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2011 | 56 | 0.100 |
Why?
|
| Rats | 2 | 2010 | 4943 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 440 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2012 | 275 | 0.090 |
Why?
|
| Vimentin | 1 | 2011 | 58 | 0.090 |
Why?
|
| Brain | 2 | 2023 | 2374 | 0.090 |
Why?
|
| Fluorouracil | 2 | 2012 | 152 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 66 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 654 | 0.090 |
Why?
|
| Genes, bcl-2 | 1 | 2011 | 20 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2011 | 138 | 0.090 |
Why?
|
| Heptanoic Acids | 1 | 2011 | 60 | 0.090 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 12 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 249 | 0.090 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2010 | 22 | 0.090 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 45 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2099 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 198 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.090 |
Why?
|
| Cognition | 2 | 2016 | 989 | 0.090 |
Why?
|
| Cadherins | 1 | 2011 | 176 | 0.090 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 78 | 0.090 |
Why?
|
| Cannabinoids | 1 | 2011 | 115 | 0.090 |
Why?
|
| Immunoblotting | 1 | 2010 | 283 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 706 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 168 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 24 | 0.080 |
Why?
|
| Weight Loss | 1 | 2014 | 642 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 149 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 797 | 0.080 |
Why?
|
| Demography | 1 | 2010 | 262 | 0.080 |
Why?
|
| Dogs | 1 | 2010 | 334 | 0.080 |
Why?
|
| Risk Factors | 4 | 2019 | 8627 | 0.080 |
Why?
|
| Species Specificity | 1 | 2010 | 545 | 0.080 |
Why?
|
| RNA Interference | 1 | 2010 | 437 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1393 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 763 | 0.080 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2009 | 119 | 0.080 |
Why?
|
| Medical Records | 1 | 2009 | 153 | 0.080 |
Why?
|
| Marijuana Smoking | 1 | 2011 | 224 | 0.080 |
Why?
|
| Floxuridine | 1 | 2008 | 5 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2016 | 1662 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 994 | 0.080 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 24 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 797 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 215 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2022 | 268 | 0.070 |
Why?
|
| Capecitabine | 1 | 2008 | 45 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1691 | 0.070 |
Why?
|
| Salvage Therapy | 2 | 2019 | 127 | 0.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 40 | 0.070 |
Why?
|
| Everolimus | 2 | 2020 | 61 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 109 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1022 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2013 | 801 | 0.070 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 52 | 0.070 |
Why?
|
| Scalp | 1 | 2006 | 29 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 447 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 621 | 0.070 |
Why?
|
| Placebos | 1 | 2006 | 198 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 103 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 385 | 0.070 |
Why?
|
| Cell Line | 1 | 2012 | 2639 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2008 | 275 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 372 | 0.070 |
Why?
|
| Cetuximab | 2 | 2017 | 91 | 0.060 |
Why?
|
| Hair Follicle | 1 | 2005 | 44 | 0.060 |
Why?
|
| Melanocytes | 1 | 2005 | 55 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 854 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 742 | 0.060 |
Why?
|
| Cannabis | 1 | 2011 | 384 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 440 | 0.060 |
Why?
|
| Monocytes | 1 | 2008 | 503 | 0.060 |
Why?
|
| Models, Biological | 1 | 2012 | 1630 | 0.060 |
Why?
|
| Safety | 1 | 2006 | 297 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2014 | 77 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 815 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2005 | 156 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2008 | 1571 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 833 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2023 | 35 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 1147 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 330 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2014 | 66 | 0.050 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 32 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2006 | 640 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 27 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 4625 | 0.050 |
Why?
|
| Asia | 1 | 2021 | 53 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 172 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 286 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 564 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2020 | 64 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 336 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 177 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 535 | 0.040 |
Why?
|
| Mice | 4 | 2019 | 14916 | 0.040 |
Why?
|
| Age Factors | 1 | 2007 | 2890 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 130 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2019 | 27 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2019 | 28 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2019 | 50 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 184 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 292 | 0.040 |
Why?
|
| Organoids | 1 | 2019 | 74 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 6 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 1178 | 0.040 |
Why?
|
| Genes, erbB-1 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2019 | 130 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 125 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 114 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 737 | 0.040 |
Why?
|
| Immune System | 1 | 2019 | 173 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2017 | 15 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2017 | 16 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 332 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 68 | 0.040 |
Why?
|
| Palliative Care | 2 | 2014 | 641 | 0.040 |
Why?
|
| Exosomes | 1 | 2018 | 91 | 0.030 |
Why?
|
| Hyperphosphatemia | 1 | 2016 | 13 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 74 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 1151 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 49 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 433 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 77 | 0.030 |
Why?
|
| Myalgia | 1 | 2015 | 15 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2015 | 75 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 36 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 86 | 0.030 |
Why?
|
| Heart | 1 | 2019 | 609 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 141 | 0.030 |
Why?
|
| Constipation | 1 | 2015 | 76 | 0.030 |
Why?
|
| Edema | 1 | 2015 | 118 | 0.030 |
Why?
|
| Gonanes | 1 | 2014 | 27 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2014 | 26 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 530 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 188 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 138 | 0.030 |
Why?
|
| United Kingdom | 1 | 2014 | 226 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2014 | 45 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 1163 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 262 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 130 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 162 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 140 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 74 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 176 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 244 | 0.030 |
Why?
|
| Syndecan-4 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 33 | 0.030 |
Why?
|
| Sirolimus | 1 | 2013 | 181 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2013 | 88 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 399 | 0.030 |
Why?
|
| Leucovorin | 1 | 2012 | 43 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 320 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 102 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 1128 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 18 | 0.020 |
Why?
|
| Midazolam | 1 | 2012 | 43 | 0.020 |
Why?
|
| Pyridones | 1 | 2013 | 123 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 481 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2012 | 62 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 119 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 113 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 83 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 157 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 635 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 295 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 344 | 0.020 |
Why?
|
| Receptor, ErbB-4 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 322 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 353 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1078 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 102 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 161 | 0.020 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2010 | 27 | 0.020 |
Why?
|
| Capsules | 1 | 2010 | 36 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 92 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 66 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4710 | 0.020 |
Why?
|
| Alopecia | 1 | 2009 | 28 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 174 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 372 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 751 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 158 | 0.020 |
Why?
|
| Anemia | 1 | 2009 | 144 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 77 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 667 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2008 | 354 | 0.020 |
Why?
|
| California | 1 | 2008 | 356 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 552 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 334 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 328 | 0.020 |
Why?
|
| DNA Repair | 1 | 2008 | 186 | 0.020 |
Why?
|
| Pain | 1 | 2011 | 710 | 0.020 |
Why?
|
| DNA Damage | 1 | 2008 | 357 | 0.020 |
Why?
|
| Colorado | 1 | 2014 | 4086 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2010 | 601 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1197 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1796 | 0.010 |
Why?
|